It has been reported that the upstream activation of several RTKs interferes with the KRASG12C blockade, and EGFR signaling appears to be a predominant mechanism underlying colorectal cancer resistance to AMG510 [49]. The gene discussed is EGFR; the disease is colorectal cancer.